Clinical Trials Logo

Atypical Anorexia Nervosa clinical trials

View clinical trials related to Atypical Anorexia Nervosa.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04421989 Completed - Anorexia Nervosa Clinical Trials

Parent Emotion Coaching for Anorexia Nervosa

Start date: June 24, 2020
Phase: N/A
Study type: Interventional

Family based treatment (FBT) is the evidence based treatment for pediatric anorexia nervosa (AN), but 50% of adolescents do not respond and the consequences for non-response are dire (e.g., 11.5% mortality rate). Expressed emotion and parental warmth are significant mechanisms of treatment outcome in adolescents with AN, which are not explicitly targeted by FBT. The current proposal is a parent emotion coaching skills group designed to augment FBT in the treatment of pediatric AN by arming high expressed emotion families with the skills necessary to implement FBT and improve treatment outcomes (e.g., weight restoration).

NCT ID: NCT03292146 Completed - Anorexia Nervosa Clinical Trials

Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

Start date: October 25, 2017
Phase: Phase 3
Study type: Interventional

This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to investigate the effect of denosumab on BMD in women with anorexia nervosa. The investigators hypothesize that 12 months of denosumab administration will result in an increase in bone mineral density, decrease in markers of bone resorption and improvement in bone microarchitecture in osteopenic women with anorexia nervosa compared with placebo. An optional extension study will offer subjects 12-month administration of open-label alendronate (an oral bisphosphonate) after the initial 12 month administration of denosumab or placebo. We hypothesize that 12 months of denosumab followed by 12 months of open-label alendronate will result in a greater increase in BMD compared to 12 months of placebo followed by 12 months of open-label alendronate. Within the group of women who receive sequential therapy with 12 months of denosumab followed by 12 months of alendronate, we hypothesize that BMD will be maintained between 12 and 24 months while on alendronate.

NCT ID: NCT02359123 Completed - Cancer Cachexia Clinical Trials

Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients

Start date: November 2016
Phase: N/A
Study type: Interventional

The main purpose in the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) is to prolong life and to improve quality of life (QoL) as far as possible. QoL in patients with CACS is directly related to loss of appetite and loss of weight. Cannabis pills are given in Israel to advanced cancer patients with various symptoms in order to improve their QoL. There is data on safety/toxicity of cannabis, and these pills are given under the regulations of the Israel Ministry of Health. The purpose of this study is to examine the influence of Cannabics capsules on improving loss of appetite and loss of weight.